NIAID – National Institute of Allergy and Infectious Diseases on Monday announced its first novel coronavirus vaccine trials in US.
The first dose was given to the first participant in Seattle Washington,conducted at Kaiser Permanente Washington Health Research Institute. A 43 year old lady Jennifer Haller was the first person to get the vaccine.
The vaccine, mRNA -1273, was developed by biotechnology company Moderna in combination with researchers from NIH- National Institutes of Health .
The healthy participants will receive two shots of the vaccine 28 days apart and will be monitored to evaluate immunogenicity and the safety of the vaccine.
In a press release, chief medical officer at Moderna said the study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2 and is expected to provide important information about safety and immunogenicity.
Speaking during a national news conference at White House, NIAID director Dr. Anthony Fauci said phase one of trial vaccine was implemented after just 65 days.
The vaccine can not cause COVID-19 since it does not contain the virus as in the case with other vaccines .The researchers hope that the vaccine will stimulate the immune system to attack the virus .